Discovery of orally active chalcones as histone lysine specific demethylase 1 inhibitors for the treatment of leukaemia
Histone lysine specific demethylase 1 (LSD1) has emerged as an attractive molecule target for the discovery of potently anticancer drugs to treat leukaemia. In this study, a series of novel chalcone derivatives were designed, synthesised and evaluated for their inhibitory activities against LSD1 in ...
Saved in:
Main Authors: | Yang Li (Author), Ying Sun (Author), Yang Zhou (Author), Xinyang Li (Author), Huan Zhang (Author), Guojun Zhang (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mechanisms of carcinogenic activity triggered by lysine-specific demethylase 1A
by: Chao Yang, et al.
Published: (2022) -
Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics
by: Ugo Chianese, et al.
Published: (2022) -
Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A)
by: Zhonghua Li, et al.
Published: (2019) -
MicroRNA let-7i Inhibits Histone Lysine Demethylase KDM5B to Halt Esophageal Cancer Progression
by: Yang Yang, et al.
Published: (2020) -
Multilocus loss of DNA methylation in individuals with mutations in the histone H3 Lysine 4 Demethylase KDM5C
by: Grafodatskaya Daria, et al.
Published: (2013)